Primary Rituximab and Maintenance
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00140582 |
Recruitment Status :
Completed
First Posted : September 1, 2005
Last Update Posted : March 13, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
-
Objectives
- Primary objective: To evaluate in patients with advanced follicular lymphoma the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy
- Secondary objective: To evaluate response rates, event driven survival endpoints (EFS, PFS, OS) and quality of life of four different chemotherapy regimens combined with rituximab, with or without maintenance with rituximab, for first line treatment of advanced stage follicular lymphoma.
- Study Design This is an international open-label, multicentre, randomized study with two treatment phases. In the induction phase patients have to respond to 1st line induction treatment in order to be eligible for randomization to the second phase of maintenance treatment or observation. After the maintenance period patients will be included in the follow up phase for 3 years.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Follicular Lymphoma | Drug: Rituximab | Phase 3 |
Study medication
- First period: Induction of response with 8 x rituximab combined with 8 cycles of CVP or 6 cycles of CHOP in 21-day cycles or 6 cycles of FCM in 28-day cycles or 6 cycles of MCP in 28-day cycles.
- Second period: rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1217 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Advanced Follicular Lymphoma Evaluating the Benefit of Maintenance Therapy With Rituximab (MabThera®) After Induction of Response With Chemotherapy Plus Rituximab in Comparison With no Maintenance Therapy |
Actual Study Start Date : | December 2004 |
Actual Primary Completion Date : | May 2007 |
Actual Study Completion Date : | December 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: A : rituximab maintenance
Maintenance with rituximab for 2 years
|
Drug: Rituximab
rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment |
No Intervention: B : no maintenance
No further treatment
|
- Progression Free Survival (PFS) [ Time Frame: number of event observed driven : 344 events or 10 years ]defined as the time from randomization to progression, relapse, death from any cause.
- Response rates, event driven survival endpoints (EFS, PFS, OS) [ Time Frame: number of event observed driven : 344 events or 10 years ]
- Quality of life [ Time Frame: number of event observed driven : 344 events or 10 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed follicular lymphoma grade 1, 2 or 3a.
- Patients previously untreated.
-
Patients with at least one of the following symptoms requiring initiation of treatment:
- Bulky disease at study entry according to the GELF criteria: nodal or extranodal mass > 7cm in its greater diameter
- B symptoms
- Elevated serum LDH or beta2-microglobulin
- involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)
- symptomatic splenic enlargement
- compressive syndrome
- pleural/peritoneal effusion
- Age must be > 18 years.
- Performance status < 2 on the ECOG scale (see appendix E).
-
Adequate hematological function within 28 days prior to registration (unless those abnormalities are related to lymphoma extension), this includes:
- Hemoglobin ≥ 8.0 g/dl (5.0 mmol/L)
- Absolute neutrophil count (ANC) ≥ 1.5 109/L
- Platelet count ≥ 100 109/L
- Women are not breast feeding, are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter.
- Having previously signed a written informed consent form.
Exclusion Criteria:
- Transformation to high-grade lymphoma (secondary to "low-grade" follicular lymphoma).
- Grade 3b follicular lymphoma.
- Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis).
- Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisone.
- Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.
- Major surgery (excluding lymph node biopsy) within 28 days prior to registration.
- Poor renal function: Serum creatinine > 2.0 mg/dl (197 μmol/L),
- Poor hepatic function: total bilirubin > 2.0 mg/dl (34 μmol/L), AST (SGOT) > 3 x the upper limit of normal unless these abnormalities are related to lymphoma.
- Known HIV infection or active HBV or HCV infection.
- Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
- Life expectancy < 6 months
- Known sensitivity or allergy to murine products
- Treatment within a clinical trial within 30 days prior to trial entry
- Adult patient under tutelage.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140582
Principal Investigator: | Gilles A Salles, MD PhD | Lymphoma Study Association |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lymphoma Study Association |
ClinicalTrials.gov Identifier: | NCT00140582 |
Other Study ID Numbers: |
PRIMA |
First Posted: | September 1, 2005 Key Record Dates |
Last Update Posted: | March 13, 2017 |
Last Verified: | March 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
lymphoma follicular maintenance |
Lymphoma Lymphoma, Follicular Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Lymphoma, Non-Hodgkin Rituximab Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |